

New Drug, Generic, and Biosimilar Pipeline Report

Q2 2026

Below is a summary of significant forthcoming drug launches of newly approved brand drugs, generics, and biosimilars.

New Drug Pipeline

GENERIC NAME	BRAND NAME (Manufacturer if drug name unavailable)	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED COST	THERAPEUTIC AREA	SPECIALTY OR TRADITIONAL
icotrokinra	(Johnson & Johnson)	Oral	March 2026	\$50,000 - \$100,000	Dermatology	Specialty
orforglipron Calcium	(Eli Lilly)	Oral	April 2026	\$10,000 - \$18,000 annually	Sleep Apnea / Weight Management	Traditional
baxdrostat	(AstraZeneca)	Oral	Q2 2026	\$5,000 - \$10,000 annually	Cardiology	Traditional
cytisinicline	(Achieve Life Sciences)	Oral	June 2026	\$1,000	Behavior Health	Traditional
TRN-257	(Tris Pharma)	Oral	June 2026	\$100,000 - \$200,000 annually	Sleep	Specialty
tavapadon	(Pfizer / Abbvie)	Oral	Q3 2026	\$10,000 - \$20,000 annually	Parkinson's Disease	Traditional
imsidolimab	(AnaptysBio; Vanda Pharmaceuticals)	Intravenous; Subcutaneous	2026	\$200,000 - \$300,000 annually	Dermatology	Specialty
tebipenem	(GSK, Spero Therapeutics)	Oral	2026	\$5,000 - \$10,000 per treatment course	Infectious disease	Traditional
insulin efsitora alfa	(Eli Lilly)	Subcutaneous	2026	\$5,000	Endocrinology	Traditional

Key

Launched MM YYYY Month and year drug was launched
Approved MM YYYY Month and year drug was approved
Date Updated release date

Withdrawn
 CRL
 EST LOE
 PROB

Drug has been withdrawn from FDA approval
 Complete Response Letter - Incomplete FDA Application
 Estimated Loss of Exclusivity Probability based on IPD Analytics' proprietary estimate of the probability of a generic launch, based on patent analysis and knowledge of generic launches

Generic Pipeline

DRUG NAME	BRAND NAME	ROUTE OF ADMINISTRATION	STATUS / EST LOE PROB	ESTIMATED	THERAPEUTIC AREA	BIOSIMILAR OR TRADITIONAL
metformin; sitagliptin	Janumet	Oral	May 2026	1,354	Endocrine: Diabetes	Traditional
sitagliptin	Januvia	Oral	May 2026	6,397	Endocrine: Diabetes	Traditional
brivaracetam	Briviact	Oral	2026	818	Epilepsy	Traditional

Biosimilar Pipeline

GENERIC NAME	BRAND NAME (Manufacturer if drug name unavailable)	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED COST	THERAPEUTIC AREA	BIOSIMILAR OR TRADITIONAL
nintedanib	Ofev	Oral	April 2026	2,979	Pulmonology	Biosimilar
Insulin glargine	Lantus	Subcutaneous	May 2026	1,800	Endocrine: Diabetes	Traditional
tofacitinib Citrate	Xeljanz	Oral	Q2 2026	4,304	Autoimmune	Biosimilar
Insulin aspart	Novolog	Subcutaneous	July 2026	1,200	Endocrine: Diabetes	Traditional
Insulin lispro	Humalog	Subcutaneous	2026	1,800	Endocrine: Diabetes	Traditional
golimumab	Simponi	Subcutaneous	2026	3,700	Autoimmune	Biosimilar
abatacept	Orencia	Subcutaneous	2026	4,900	Autoimmune	Biosimilar
omalizumab	Xolair	Subcutaneous	2026	3,900	Autoimmune	Biosimilar

Nothing herein is or shall be construed as a promise or representation regarding past or future events and Serve You Rx expressly disclaims any and all liability relating to the use or reliance on the information contained in this publication. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Serve You Rx.

*New Formulation of an Existing Product

Source: IPD Analytics, 2025

ServeYouRx.com | 800-759-3203



Key

Launched MM YYYY Month and year drug was launched
Approved MM YYYY Month and year drug was approved
Date Updated release date

Withdrawn
 CRL
 EST LOE PROB

Drug has been withdrawn from FDA approval
 Complete Response Letter - Incomplete FDA Application
 Estimated Loss of Exclusivity Probability based on IPD Analytics' proprietary estimate of the probability of a generic launch, based on patent analysis and knowledge of generic launches